Welcome to our dedicated page for Avalon Globocare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalon GloboCare Corp. (NASDAQ: ALBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents. These filings describe Avalon as a commercial‑stage company focused on precision diagnostic consumer products, cellular therapy intellectual property, generative AI publishing and software, and commercial real estate operations. Through its SEC reports, Avalon details material events such as acquisitions, financing arrangements, Nasdaq listing matters, and progress on its proposed merger with YOOV Group Holding Limited.
In recent Form 8‑K filings, Avalon has reported the acquisition of RPM Interactive, Inc. through its subsidiary Avalon Quantum AI, LLC, adding a generative AI powered SaaS platform for automated short‑form video creation. Other 8‑K and 8‑K/A filings outline senior secured promissory notes, bridge notes, waivers and amendments, unregistered sales of equity securities, and changes to preferred stock designations, including Series C and Series E preferred stock. Filings also document Nasdaq correspondence regarding compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b) and the company’s steps to address those requirements.
SEC filings further describe Avalon’s Agreement and Plan of Merger with YOOV Group Holding Limited and the related Registration Statement on Form S‑4, which contains a preliminary proxy statement/prospectus. These documents explain the structure of the proposed merger, the conditions to closing, and the anticipated focus on Artificial Intelligence‑as‑a‑Service (AIaaS) solutions following completion. Additional disclosures cover the company’s share issuances, beneficial ownership limitations, and updates on outstanding notes and conversion terms.
On Stock Titan, users can review Avalon’s 8‑K, 8‑K/A, 10‑K, and other SEC filings, while AI‑powered tools help summarize complex sections, highlight key terms, and surface information on topics such as financing, preferred stock features, Nasdaq listing status, and merger‑related disclosures. This makes it easier to understand how Avalon’s precision diagnostics, cellular therapy IP, AI software assets, and capital structure are reflected in its official regulatory record.
Avalon GloboCare Corp. director Michael Mathews reported receiving 1,364.840 shares of the company’s Series E Non-Voting Convertible Preferred Stock at a stated price of $0 per share. These preferred shares were issued in exchange for 2,600,000 common shares of RPM Interactive, Inc. as part of Avalon GloboCare’s acquisition of RPM.
Each share of this Series E preferred stock is perpetual, so it has no expiration date, and it becomes convertible into Avalon GloboCare equity at any time from and after May 12, 2026, or earlier if the company consents in writing.
Avalon GloboCare Corp. director Mathews Michael filed an initial insider ownership report on Form 3. The filing establishes his status as a director of the company but does not list any specific share transactions or changes in ownership.
Avalon Globocare Corp. completed an amended transaction to sell 100% of the membership interests of its subsidiary Avalon RT 9 Properties, LLC, which owns the company’s Freehold, New Jersey office property, to its board chairman Wenzhao Lu.
The amended deal provides total consideration of $9,000,000, consisting of $3,100,000 in cash previously advanced under the original agreement and the satisfaction in full of an approximately $5,900,000 mortgage balance. Following closing, Avalon is released from all obligations as guarantor on that mortgage.
The company also amended a $375,000 unsecured bridge note dated December 11, 2025, extending the first, second, and third payment deadlines to March 16, 2026, April 15, 2026, and May 15, 2026, respectively.
Avalon Globocare Corp. entered into a financing deal with Vanquish Funding Group involving a $233,910 promissory note, sold for $207,000 with a $26,910 original issue discount and a one-time 12% interest charge. The note requires seven monthly payments starting August 15, 2026 and matures on February 15, 2027. If an event of default occurs, the lender can demand 150% of the default amount and the note becomes convertible into common stock at 75% of the lowest trading price over the prior ten trading days, subject to a 19.99% issuance cap. Avalon plans to use the proceeds for general working capital and paid a $10,000 fee to Digital Offering LLC. The company also issued 300,000 common shares to consultants for services rendered, receiving no cash proceeds.
Avalon GloboCare Corp. is convening a virtual special meeting on to seek stockholder approval for seven proposals that would clear Nasdaq compliance for multiple equity-related transactions and permit a reverse stock split.
The items include approvals to potentially issue shares on conversion of July 2025 and December 2025 notes (seeking relief for up to 485,816 and 890,321 shares, respectively), approval to permit conversion of Series C convertible preferred stock, approval of an exchange of Series D preferred for 2,074,689 common shares to the Chairman, issuance of 450,000 restricted shares to an advisor, authority to effect a reverse split between 1-for-2 and 1-for-25, and an adjournment proposal.
Avalon GloboCare Corp. reported that its subsidiary, Avalon Quantum AI LLC, filed a third U.S. provisional patent for its Catch-Up generative AI video platform. The application, titled “Systems and Methods for Audience-Adaptive Generation of Evidence-Preserving Commentary Video Variants” (No. 63/961,892), was filed on February 18, 2026.
The technology is designed to create multiple personalized commentary video versions from a shared, verified evidence framework while preserving factual integrity. It tailors structure, tone, pacing, and presentation for different audience segments and formats, with potential uses in financial commentary, sports highlights, and brand-safe marketing content.
Avalon GloboCare Corp. is asking the SEC to withdraw its previously filed registration statement on Form S-4 related to a planned business combination with YOOV Group Holding Limited. The merger agreement has been terminated, so the company no longer plans to proceed with the related securities offering.
The filing states that the registration statement was never declared effective and that no securities have been, or will be, sold or issued under it. Avalon also asks that any SEC filing fees already paid be credited for potential future use under applicable rules.
Avalon GloboCare Corp. filed a current report to share information it released in a press release dated February 2, 2026. The company announced the conversion of the majority of its outstanding debentures, indicating a significant change in how this debt is structured. The press release describing this conversion is attached as an exhibit and is treated as furnished under Regulation FD rather than filed under the securities laws.
Avalon GloboCare Corp. terminated its planned merger with YOOV Group Holding Limited. On January 21, 2026, Avalon, its Nexus MergerSub subsidiary, and YOOV signed a Mutual Termination and Release Agreement that ends the March 7, 2025 Merger Agreement, with only specified surviving provisions remaining.
The parties agreed that no termination fee, expense reimbursement, or other payment is owed by either side, and each granted the other a broad mutual release of claims related to the proposed merger, subject to exceptions for rights under the termination deal, certain surviving provisions, and claims based on fraud or intentional misrepresentation. They also agreed to a mutual non‑disparagement covenant lasting three years and reciprocal indemnification for breaches, capped at $500,000 per side, excluding fraud or intentional misrepresentation.
Separately, Avalon disclosed that its subsidiary Avalon Quantum AI LLC filed a U.S. provisional patent application covering systems and methods for evidence‑constrained, audience‑adaptive automated commentary videos.
Avalon Globocare Corp. filed a current report to share that it issued a press release providing updates on its KetoAir™ breathalyzer device. The filing states that the press release, attached as an exhibit, is being furnished under Regulation FD, which is used to distribute important company information broadly and at the same time to all investors. The company also clarifies that this information is not considered “filed” for liability purposes under securities laws unless specifically incorporated into another filing.